Skip to main content

Friday, Nov. 20, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $23.06 to $5,010,000.00.

Highlighted Stocks Traded by Insiders:

Credit Acceptance (CACC) - FREE Research Report

Booth Kenneth, who is Chief Financial Officer at Credit Acceptance, bought 5,000 shares at $164.80 on Nov. 20, 2015. Following this transaction, the Chief Financial Officer owned 29,406 shares meaning that the stake was boosted by 20.49% with the 5,000-share transaction.

The shares most recently traded at $170.71, up $5.91, or 3.46% since the insider transaction. Historical insider transactions for Credit Acceptance go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 1,624
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 1,624
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 346

The average volume for Credit Acceptance has been 165,500 shares per day over the past 30 days. Credit Acceptance has a market cap of $3.4 billion and is part of the financial sector and financial services industry. Shares are up 24.45% year-to-date as of the close of trading on Friday.

Credit Acceptance Corporation provides automobile dealers financing programs, and related products and services that enable them to sell vehicles to consumers. The company has a P/E ratio of 11.8. Currently, there are no analysts who rate Credit Acceptance a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CACC - FREE

TheStreet Quant Ratings

rates Credit Acceptance as a

TheStreet Recommends

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Credit Acceptance Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 397 shares at $18.17 on Nov. 20, 2015. Following this transaction, the Senior V.P., Research owned 387,332 shares meaning that the stake was reduced by 0.1% with the 397-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 397 shares at $18.17 on Nov. 20, 2015. Following this transaction, the Svp, Cfo owned 142,738 shares meaning that the stake was reduced by 0.28% with the 397-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 650 shares at $18.11 on Nov. 20, 2015. Following this transaction, the Senior VP, Pharmaceutical Scie owned 94,068 shares meaning that the stake was reduced by 0.69% with the 650-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 603 shares at $18.17 on Nov. 20, 2015. Following this transaction, the SVP & General Counsel owned 116,410 shares meaning that the stake was reduced by 0.52% with the 603-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 603 shares at $18.17 on Nov. 20, 2015. Following this transaction, the Senior VP, Development and Chi owned 90,801 shares meaning that the stake was reduced by 0.66% with the 603-share transaction.

The shares most recently traded at $17.90, down $0.27, or 1.51% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,138
  • 12-Week # shares sold: 3,651
  • 24-Week # shares sold: 42,217

The average volume for Momenta Pharmaceuticals has been 770,400 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 47.01% year-to-date as of the close of trading on Friday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 5 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings

rates Momenta Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full

Momenta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

JM Smucker (SJM) - FREE Research Report

Lemmon David J, who is Vice President at JM Smucker, sold 1,062 shares at $120.00 on Nov. 20, 2015. Following this transaction, the Vice President owned 0 shares meaning that the stake was reduced by 100% with the 1,062-share transaction.

The shares most recently traded at $124.31, up $4.31, or 3.47% since the insider transaction. Historical insider transactions for JM Smucker go as follows:

  • 4-Week # shares bought: 100
  • 4-Week # shares sold: 250
  • 12-Week # shares bought: 100
  • 12-Week # shares sold: 8.3 million
  • 24-Week # shares bought: 100
  • 24-Week # shares sold: 13.2 million

The average volume for JM Smucker has been 1.2 million shares per day over the past 30 days. JM Smucker has a market cap of $14.5 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 21.2% year-to-date as of the close of trading on Friday.

The J. M. Smucker Company manufactures and markets branded food products worldwide. It operates through four segments: U.S. Retail Coffee; U.S. Retail Consumer Foods; U.S. Retail Pet Foods; and International, Foodservice, and Natural Foods. The stock currently has a dividend yield of 2.21%. The company has a P/E ratio of 37.3. Currently, there are 3 analysts who rate JM Smucker a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SJM - FREE

TheStreet Quant Ratings

rates JM Smucker as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

JM Smucker Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.